ENDOKANABİNOİD SİSTEMİN , ENERJİ METABOLİZMASI VE OBEZİTEYE ETKİSİ

Abstract

Son zamanlarda hint keneviri ve onun majör psikotropik komponenti olan, ∆9-tetrahidrokanabinol, KB1 kanabinoid reseptörleri ve endojen bağlarını içeren endokanabinoidlerin, enerji dengesini kontrol ederek iştahı stimüle ettiği ve vücut ağırlığını artırdığı belirlenmiştir. Hayvan çalışmalarında ve insanlarda yapılan klinik çalışmalarda, endokanabinoid sistemin, besin alımını santral ve periferik mekanizmalarla kontrol ettiği, lipogenez ve yağ birikimini stimüle ettiği gösterilmiştir. Bu makalede, endokanabinoid sistemin oluşumu, reseptörleri, bağları ve bu fizyolojik sistemin enerji metabolizması ve obezite üzerine olan etkisi tartışılmıştır.

Anahtar Kelimeler: Endokanabinoid system, Esrar, Obezite , Enerji metabolizması

Keywords

• Endokanabinoid system, Esrar, Obezite , Enerji metabolizması

References

1. Pagotta U, Vicennati V, Pasquali R. The
2. endocannabinoid system and the treatment of obesity.
3. Annals of Medicine; 2005:270-275.
4. Define Understand Ackowledge Highligt Review. The
5. Endocannabinoid System and the Regulation of Energy
6. Metabolism. Eds: Jorge Plutzky and Stephen C. Woods.
7. Brought by Sanofi-Aventis U.S.LLC. Diabetes Care
8. ;(9)

9. Cota D, Woods SC. The role of the endocannabinoid
10. system in the regulation of energy homeostasis.
11. Endocrinology and Diabetes 2005;12 (5):338-351.
12. Ravinet-Tirollou C, Delgorge C, Menet C, Arnone M,
13. Soubrie P. CB1 cannabinoid receptor knockout in mice
14. leads to leannes, resistance to diet-induced obesity and
15. enhanced leptin sensitivity. Internal Journal Obesity
16. Related Metabolic Disorder 2004;28:640-648.
17. Ravinet-Trillou C, Arnone M, Delgorge C, Gonalans N,
18. Keane P, Maffrand JP, Soubrie P. Anti-obesity effect of
19. SR141716, a CB1 receptor antagonist, in diet-induced
20. obese mice. American Journal Physiology Regul Integr
21. Comp Physiology 2003;284:R345-R353.
22. Di Marzo V, Bifulco M, De Petrocellis L. The
23. endocannabinoid system and its therapeutic exploitation.
24. Naturel Reviews/ Drug Discovery 2004;3:771-84.
25. Cota D, Marsicano G,Tschop M, et al.The endogenous
26. cannabinoid system affects energy balance via central
27. orexigenic drive and peripheral lipogenesis. The Journal
28. of Clinical Investigation 2003;112:423-31
29. Sarnataro D, Pisanti S, Santoro A, Gazzerro P,
30. Malfitano AM, Laezza C, Bifulco M. The Cannabinoid
31. CB1 Receptor Antagonist Rimonabant (SR141716)
32. Inhibits Human Breast Cancer Cell Proliferation through
33. a Lipid Raft-Mediated Mechanism Mol Pharmacol
34. ; 70:1298-1306,
35. -
36. Marmara Medical Journal 2007;20(3);202-214
37. Emel Tüfekçi Alphan, ark.
38. Endokanabinoid sistemin , enerji metabolizması ve obeziteye etkisi
39. Mechoulam R, Berry EM, Avraham Y, Marzo VD,
40. Fride E. The Endocannabinoid System, mechanism of
41. action and Function. Endocannabinoids, feeding and
42. suckling-from our perspective. International Journal of
43. Obesity 2006;30:24-28.
44. Mattes RD, Engelman K, Shaw LM, Elsohly MA.
45. Cannabinoids and appetite stimulation. Pharmacol
46. Biochem Behav 49:187–195, 1994.
47. Osei-Hyiaman D, l DePetrilloM, Pacher P, Liu J,
48. Radaeva S, Bátkai S, Harvey-White J,Mackie K,
49. Offertáler L, Wang L, Kunos G. Endocannabinoid
50. activation at hepatic CB1 receptors stimulates fatty acid
51. synthesis and contributes to diet-induced obesity.
52. Journal of Clinical Investigation 2005 ;115:1298–1305.
53. Howlett A C, Barth F, Bonner TI, Cabral G, Casellas P,
54. Devane WA, Felder CC, Herkenham M, Mackie K,
55. Martin BR, Mechoulam R, Pertwee RG. International
56. Union of Pharmacology. XXVII. Classification of
57. Cannabinoid Receptors. International Union
58. Pharmacology 2002; 54 (2):161-202.
59. Gıuffrıda A, Beltramo M, Pıomellı D. Mechanisms of
60. Endocannabinoid Inactivation: Biochemistry and
61. Pharmacology. The Journal of Pharmacology and
62. Experımental Therapeutıcs 2001;298:7–14.
63. Korner J, Aronne LJ. The emerging science of body
64. weight regulation and its impact on obesity treatment.
65. Journal Cilinical Investigation 2003;111:565-570.
66. Faroogi IS, O’Rahilly S. Recent advances in the genetics
67. of severe childhood obesity. Arch Dis Child 2000; 83:
68. -34.
69. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S,
70. Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T,
71. Kunos G. Leptin-regulated endocannabinoids are
72. involved in maintaining food intake. Nature (London).
73. ;410:822–825.
74. Fride E, BregmanT, Tim Kirkham TC.
75. Endocannabinoids and Food Intake: Newborn Suckling
76. and Appetite Regulation in Adulthood. Experimental
77. Biology and Medicine 2005;230:225-234.
78. Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA,
79. Mitchell SE, Williams LM, Hawley SA, Hardie DG,
80. Grossman AB, Korbonits M. Cannabinoids and Ghrelin
81. Have Both Central and Peripheral Metabolic and
82. Cardiac Effects via AMP-activated Protein Kinase.
83. J.Biol.Chem.,2005;280(26):25196-25201.
84. Jamshidi N, Taylor DA. Anandamid administration into
85. the ventromedial hypotalamıus stimulates appetite in
86. rats. British Journal Pharmacology 2001;134:1151-1154.
87. Kirkham TC, Williams CM, Feza F, Marzo V.
88. Endocannabinoid levels in rat limbic forebrain and
89. hypothalamus in relation to fasting, feeding and satiation
90. : stimulation of eating by arachidonoyl glycerol. British
91. Journal Pharmacology 2002;136:550-557.
92. Sato M, Suziki S, Senoo H. Hepatic stellate cells: unique
93. characteristics in cell biology and phenotype. Cell Struct
94. Funct. 2003;28:105-112.
95. Hao S, Avraham Y, Mechoulam R, Berry EM. Low dose
96. anandamide affects food intake, cognitive function,
97. neurotransmitter and corticosterone levels in dietrestricted
98. mice. Eur J Pharmacology 2000;392:147-156.
99. Powell EE, Jonsson JR, Clouston AD. Steatosis: Cofactor
100. in other liver disease .An update. Annals of
101. Hepatology 2005;42: 5-13.
102. Valdes DZ, Rodriquez GP, Tapia NCC, et al.The
103. endocannabinoid system in chronic liver disease .
104. Annals of Hepatology 2005;42:248-254.
105. Sipe JC, Waalen J, Gerber A, et al.Oweweight and
106. obesity associated with a missense polymorphism in
107. fatty acid amide hydrolase (FAAH). Internal Journal
108. Obesity Related Metabolic Disorders 2005;29:755-759.
109. Engeli S, Bohnke J, Feldpausch M, et al. Activation of
110. the peripheral endocannabinoid system in human
111. obesity. Diabetes 2005;54:2838-2843.
112. Bensaid M, Gary-Bobo M, Esclangon A, et al. The
113. cannabinoid CB1 receptor antagonist SR141716
114. increases Acrp30 mRNA expression in adipose tissue of
115. obese fa/fa rats and cultured adipocyte cells. Mol
116. Pharmacology 2003;63:908-914.
117. Lichtman AH, Cravatt BF. Food for thought:
118. endocannabinoid modulation of lipogenesis Journal
119. Clinical Investigation 2005 ;115(5): 1130–1133.
120. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R.
121. The emerging role of the endocannabinoid system in
122. endocrine regulation and energy balance. Endocrine
123. Reviews 2005; 27 (1): 73-100.
124. Druce M, Bloom SR. The regulation of appetite.
125. Archives of Disease in Childhood 2006;91:183-187.
126. Williams CM, Kirkham TC. Anandamide induces
127. overeating: mediation by central cannabinoid receptors.
128. Psychopharmacology 1999;143:315-317.
129. Pacher P, Bátkai S, Kunos G. The Endocannabinoid
130. System as an Emerging Target of Pharmacotherapy.
131. Pharmacol Rev 2006;58:389-462.
132. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O,
133. Rössner S, RIO-Europe Study Group. Effects of the
134. cannabinoid-1 receptor blocker rimonabant on weight
135. reduction and cardiovascular risk factors in overweight
136. patients: 1 year experience from the RIO-Europe study.
137. Lancet 2005:1389-97.
138. Despres JP, Golay A, Sjostorm L, et al. Effects of
139. rimonabant on metabolic risk factors in overweight
140. patients with dyslipidemia. New England Journal of
141. Medicine 2005; 353:2121-2134.
142. Pi-Sunyer FX, Aronne LJ, Heshmati HM et al. Effect of
143. rimonabant, a cannabinoid -1 receptor blocker, on
144. weight and cardiometabolic risk factors in overweight or
145. obese patients: RIO-North America: a randomized
146. controlled trial. JAMA 2006;295:761-775.
147. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal
148. LF, Efficacy and tolerability of rimonabant in
149. overweight or obese patients with type 2 diabetes: a
150. randomised controlled study The Lancet
151. ;368:16601672.
152. Cleland SJ, Sattar N. Does rimonabant pull its weight
153. for type 2 diabetes? The Lancet 2006:368: 1632-1634.
154. Horvath TL. Endocannabinoids and the regulation of
155. body fat: the smoke is clearing. The Journal of Clinical
156. Investigation. 2003 ;112:323–326.